Indivior Pharmaceuticals, Inc. INDV 深 沪
等待开盘 07-06 09:30:00 美东时间
39.80
-0.450
-1.12%
华盛通- 最 高40.81
- 今 开40.14
- 成交量 148.88万股
- 最 低 39.56
- 昨 收 40.25
- 总市值 47.05亿
- 52周最高 42.81
- 市盈率 静 24.26
- 换手率 1.26%
- 52周最低 15.00
- 委 比 47.98%
- 总股本 1.18亿
- 历史最高 42.81
- 量 比 0.58
- 振 幅 3.11%
- 历史最低 7.33
- 每 手 1
- 风险率 6.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Bloom Energy涨8.37%，Intuitive Machines涨5.47%
Bloom Energy涨8.37%；Intuitive Machines涨5.47%；万国数据涨3.23%
07-01 15:01
美股夜盘 | Bloom Energy涨7.92%，Intuitive Machines涨6.03%
Bloom Energy涨7.92%；Intuitive Machines涨6.03%；Voyager Technologies涨3.57%
07-01 13:01
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46
Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.
06-18 20:49
Shares of pharmaceutical companies are trading higher as investors rotate out of chips stocks and move into non-tech industries.
Shares of pharmaceutical companies are trading higher as investors rotate out o...
06-05 02:13
Indivior Pharma Announces Findings From Two New Real-World Evidence Studies Show Adherence To Extended-Release Buprenorphine Is Associated With Lower Relapse Risk And Reduced Healthcare Utilization
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly
05-20 21:03
财报速睇 | Indivior Pharmaceuticals, Inc. 2026财年Q1营收3.17亿美元，同比增长19.2%；归母净利润0.89亿美元，同比增长89.4%
华盛资讯5月1日讯，Indivior Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收3.17亿美元，同比增长19.2%，归母净利润0.89亿美元，同比增长89.4%。
05-01 04:49
财报速睇 | Indivior Pharmaceuticals, Inc. 2026财年Q1营收3.17亿美元，同比增长19.2%；归母净利润0.89亿美元，同比增长89.4%
华盛资讯4月30日讯，Indivior Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收3.17亿美元，同比增长19.2%，归母净利润0.89亿美元，同比增长89.4%。
04-30 21:18
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est
Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.125 billion-$1.195 billion to $1.215 billion-$1.285 billion vs $1.156 billion estimate.
04-30 19:04
Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate
Indivior (NASDAQ:INDV) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.66 by 45.45 percent. This is a 134.15 percent increase over earnings of $0.41 per share from the same
04-30 19:02
